8-K: INmune Bio Reports Mixed Q2, Advances Cancer & Alzheimer's Programs

INmune Bio announced its second quarter 2025 financial results, reported positive Phase I/II INKmune trial data, and provided updates on its XPro and CORDStrom platforms.

Summary

• Q2 2025 net loss attributable to common stockholders increased to $24.5 million, compared to $9.7 million in Q2 2024, primarily due to a $16.5 million impairment charge.
• The Phase I/II CaRe PC trial of INKmune for metastatic castration-resistant prostate cancer met its primary (safety) and secondary (NK cell activation) endpoints and is now closed to enrollment.
• The MINDFuL Phase 2 trial for XPro in Mild Cognitive Impairment and early Alzheimer's disease missed its primary cognitive endpoints in the overall population but showed a positive impact in a pre-defined subset of 100 patients with inflammation biomarkers.
• The company closed a $19 million registered direct offering and reported $33.4 million in cash and cash equivalents as of June 30, 2025.
• Key management changes include David Moss appointed President & CEO, Cory Ellspermann as Interim CFO, and Kelly Ganjei as Chairman of the Board.

Sentiment

Score: 5

Explanation: While there are positive clinical updates for INKmune and CORDStrom, the significant increase in net loss due to an impairment charge and the failure of XPro's MINDFuL trial to meet its primary endpoints in the overall population weigh negatively. The capital raise provides liquidity but also indicates ongoing funding needs. The mixed results balance out, leading to a neutral to slightly negative sentiment.

Positives

• The INKmune Phase I/II CaRe PC trial for metastatic castration-resistant prostate cancer met its primary (safety) and secondary (NK cell activation and proliferation) endpoints.
• INKmune demonstrated evidence of direct tumor cell killing, with some individual tumor lesions reducing in size or completely disappearing during treatment.
• XPro showed a positive impact on the primary cognitive endpoint EMACC in a pre-defined subset of 100 patients (50%) with two or more biomarkers of inflammation in the MINDFuL Phase 2 trial.
• XPro significantly reduces amyloid formation and improves clinical measures of brain function in patients with Traumatic Brain Injury (TBI), as presented at the Keystone Symposia.
• CORDStrom received a favorable written opinion from the United States Patent and Trademark Office (USPTO) on all claims in its international patent application PCT/US25/17028.
• A partnership with the Cell and Gene Therapy Catapult (CGT Catapult) was established to develop large-scale, commercial-ready manufacturing for CORDStrom.
• The company successfully closed a $19 million registered direct offering, enhancing its cash position.
• Cash and cash equivalents increased to $33.4 million as of June 30, 2025, from $20.9 million at December 31, 2024.

Negatives

• Net loss attributable to common stockholders significantly increased to $24.5 million for the quarter ended June 30, 2025, compared to $9.7 million for the same period in 2024.
• The MINDFuL Phase 2 trial for XPro in 208 patients with Mild Cognitive Impairment and early Alzheimer's disease missed its primary cognitive endpoints in the overall modified mITT patient population.
• An impairment of acquired in-process research and development intangible assets of $16.5 million was recorded during the quarter ended June 30, 2025.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• Actual results and the timing of certain events and circumstances may differ materially from forward-looking statements due to various risks and uncertainties.
• Product candidates (CORDStrom, XPro1595, and INKmune) have not been approved by the US Food and Drug Administration (FDA) or any regulatory body, and there is no assurance of future approval.
• Risks and uncertainties relate to the company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding is crucial for the company to continue its operations through 2026 and to conduct research and development, clinical studies, and future product commercialization.
• Risks are associated with the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

The company plans to advance the INKmune program by designing a randomized Phase 2b trial in patients with less severe disease. An End of Phase 2 meeting with the FDA for the MINDFuL trial is expected in Q4 2025, with a publication on results anticipated in August 2025. The company remains on track to file a Marketing Authorization Application (MAA) in the UK and Biologic License Application (BLA) for CORDStrom in RDEB by mid-2026, and plans to develop additional CORDStrom indications through non-dilutive funding or partnerships.

Management Comments

• "INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease." Dr. Mark Lowdell, CSO at INmune Bio.
• "Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing." Dr. Mark Lowdell, CSO at INmune Bio.
• "This [partnership with CGT Catapult] is an essential part of our ambitious timeline to transfer the manufacturing site, validate the large-scale manufacturing process and all of the analytical assays in time for MAA and BLA submissions next year."
• "We believe this [independent statistical analysis of CORDStrom RDEB data] will enrich the data presented by the Sponsor previously and we anticipate the data being available in Q4."
• "Having reviewed the current data, we concluded that the CARE-PC trial has provided all the data needed to design a future randomized trial and we have closed the trial to further recruitment to ensure completion of follow-up by end of Q4 of 2025 as planned."
• "We have ambitious plans to develop a pipeline of additional indications for CORDStrom which we will pursue with non-dilutive funding or partnerships."

Industry Context

The biotechnology industry, particularly in oncology and neurodegenerative diseases, relies heavily on successful clinical trial outcomes and robust financial backing. INmune Bio's focus on innate immune system modulation positions it in a competitive landscape with other companies developing immunotherapies and precision medicines. The mixed results for XPro in Alzheimer's highlight the significant challenges in developing treatments for complex neurological disorders, where many trials fail to meet primary endpoints. The positive safety and preliminary efficacy signals for INKmune in prostate cancer, along with the strategic manufacturing partnership for CORDStrom, indicate progress in key therapeutic areas, aligning with the industry's push for novel cancer and rare disease treatments.

Comparison to Industry Standards

• The MINDFuL Phase 2 trial's failure to meet primary cognitive endpoints in the overall population for XPro is common in Alzheimer's drug development, where many promising candidates struggle to show statistically significant clinical benefits. For example, Biogen's Aduhelm faced significant controversy despite showing some amyloid plaque reduction, and many other amyloid-targeting drugs have failed. The observed small effect sizes for XPro, while favoring the drug, are below the typical threshold for clear clinical relevance (Cohen's d of 0.2).
• The positive safety profile and evidence of NK cell activation and tumor lesion reduction for INKmune in metastatic castration-resistant prostate cancer are encouraging for a Phase I/II trial, especially given the challenges of treating advanced cancers. This aligns with the growing interest in NK cell-based immunotherapies, which are seen as a promising alternative or complement to T-cell therapies like CAR-T, with companies like Fate Therapeutics and Nkarta Therapeutics also developing NK cell platforms.
• The favorable patent opinion and manufacturing partnership for CORDStrom are critical steps for a cell therapy platform, addressing scalability and intellectual property, which are major hurdles in the cell and gene therapy sector. This positions CORDStrom to potentially compete with other mesenchymal stem cell therapies in rare diseases, though specific comparable projects and results are not detailed in the filing.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Mixed impact due to increased net loss and XPro trial miss, balanced by positive INKmune data and capital raise. Management changes could signal strategic shifts.
• Patients (mCRPC): Positive outlook for future treatment options with INKmune showing promising safety and preliminary efficacy, leading to a planned Phase 2b trial.
• Patients (Alzheimer's/MCI): Disappointment for the overall MINDFuL trial results, but a glimmer of hope for a subset of patients with inflammation biomarkers.
• Patients (RDEB): Positive progress with CORDStrom patent and manufacturing, with anticipated data release in Q4 2025, offering hope for a systemic therapy.
• Employees: Management changes may lead to organizational adjustments. Continued clinical progress provides job security and potential for growth.
• Regulatory Bodies (FDA, EMA): Ongoing engagement with FDA for XPro, and planned MAA/BLA submissions for CORDStrom indicate active regulatory pathways.

Next Steps

• Design a randomized Phase 2b trial for INKmune in patients with less severe prostate cancer.
• An End of Phase 2 meeting with the FDA regarding the MINDFuL trial is expected in Q4 2025.
• File a publication on the MINDFuL trial results expected in August 2025.
• File a Marketing Authorization Application (MAA) in the UK and Biologic License Application (BLA) for CORDStrom in RDEB by mid-2026.
• Develop a pipeline of additional indications for CORDStrom, pursuing non-dilutive funding or partnerships.
• Anticipate additional data from Greater Orman Street Hospital on RDEB patients treated with CORDStrom in Q4 2025.
• Release more patient data from the INKmune ongoing Phase 2 trial in metastatic castration-resistant prostate cancer as it becomes available.
• Completion of follow-up for the INKmune CaRe PC trial by end of Q4 2025.

Key Dates

Recommendation

The filing presents a mixed bag of results. While the INKmune trial showed promising safety and preliminary efficacy signals in a difficult-to-treat cancer, and CORDStrom is advancing with patent and manufacturing milestones, the significant increase in net loss due to an impairment charge and, more importantly, the failure of the XPro MINDFuL trial to meet its primary cognitive endpoints in the overall Alzheimer's population are notable negatives. The positive signal in a pre-defined subset for XPro is encouraging but requires further validation. The $19 million capital raise provides some financial runway, but the company's long-term funding needs remain a risk. Given the combination of clinical progress in some areas and setbacks in others, alongside financial considerations, a "hold" recommendation is appropriate as investors await further clarity on XPro's path forward, more robust CORDStrom data, and the next steps for INKmune.

Keywords

INmune Bio, INMB, INKmune, Prostate Cancer, mCRPC, NK cells, XPro, Alzheimer's, MCI, Neuroinflammation, CORDStrom, RDEB, Biotechnology, Clinical Trials, Immunology, Oncology, Cell Therapy, Financial Results, SEC Filing